Esperion Therapeutics (ESPR) Capital Expenditures (2012 - 2026)

Esperion Therapeutics has reported Capital Expenditures for 12 years, with the latest figure at $189000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $189000.0; the trailing twelve-month figure through Mar 2026 stood at $378000.0 (up 293.85% YoY), and the FY2025 full-year result was $189000.0, changed N/A from the prior year.
• Capital Expenditures for Q1 2026 stood at $189000.0, roughly flat from $189000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $195000.0 in Q1 2024, with the low at -$317000.0 in Q4 2024.
• Historically, Capital Expenditures has averaged $63000.0 across 3 years, with a median of $178000.0 in 2024.
• The largest YoY upside for Capital Expenditures was 159.62% in 2025 against a maximum downside of 159.62% in 2025.
• Esperion Therapeutics' Capital Expenditures stood at -$317000.0 in 2024, then jumped by 159.62% to $189000.0 in 2025, then changed by 0.0% to $189000.0 in 2026.
• The last three Capital Expenditures figures came in at $189000.0 (Q1 2026), $189000.0 (Q4 2025), and -$317000.0 (Q4 2024), per Business Quant data.